35 research outputs found
Clinical and cognitive risk factors for psychotic symptoms in 22q11.2 deletion syndrome: a transversal and longitudinal approach
Affective reactivity of language symptoms, startle responding, and inhibition in schizophrenia
Neurocognitive Deficits in Adolescents With Schizophrenia: Longitudinal Stability and Predictive Utility for Short-Term Functional Outcome
Neurocognitive Functions in Patients With Remitted and Nonremitted Schizophrenia: A Cross-Sectional Study
Combined Analysis of Resting-State fMRI and DTI Data Reveals Abnormal Development of Function-Structure in Early-Onset Schizophrenia
Neuropsychological Profile in Early-Onset Schizophrenia-Spectrum Disorders: Measured With the MATRICS Battery
Trouble de l’attention avec ou sans hyperactivité et schizophrénie infantile : complexité du diagnostic différentiel
Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis
The primary purpose of this study was to compare changes in cognition in early-onset psychosis after 6-months treatment with quetiapine or olanzapine. This is a randomized, single-blind, 6-month study in 50 adolescents with a diagnosis of early-onset psychosis. Patients were randomized to quetiapine (n = 24) or olanzapine (n = 26). A thorough neuropsychological battery was administered at baseline and after 6-month treatment. Out of the total sample included in the study, 32 patients completed at least 6-months treatment with the assigned medication (quetiapine, n = 16; olanzapine, n = 16). No changes were observed in cognitive performance after 6-month treatment with quetiapine or olanzapine. Although some trends toward cognitive improvement were observed for the olanzapine group after 6-month treatment, neither group showed statistically significant gains. Furthermore, there was no evidence of any differential efficacy of olanzapine or quetiapine on cognitive improvement in this sample of adolescents with psychosis